about
Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferretsDried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate--a validated assay for the clinic.Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.A clinically relevant pharmacokinetic interaction between cyclosporine and imatinibPharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients.The effects of melatonin on sleep-wake rhythm of daytime haemodialysis patients: a randomized, placebo-controlled, cross-over study (EMSCAP study)The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study.The role of melatonin treatment in chronic kidney disease.Monitoring antigen-specific biologics: current knowledge and future prospects.A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.Population pharmacokinetics of haloperidol in terminally ill adult patients.Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol.An observational study on disturbed peripheral circadian rhythms in hemodialysis patients.Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers.Quantification of Acetaminophen and Its Metabolites in Plasma Using UPLC-MS: Doors Open to Therapeutic Drug Monitoring in Special Patient Populations.A fast and sensitive LC-MS/MS method for the quantification of fosfomycin in human urine and plasma using one sample preparation method and HILIC chromatography.Simultaneous determination of nine β-lactam antibiotics in human plasma by an ultrafast hydrophilic-interaction chromatography-tandem mass spectrometry.Stability of colistimethate sodium in a disposable elastomeric infusion device.Development and Validation of an HPLC-UV Assay to Quantify Plasma Levels of Sulfametrol: A Preferential Antibiotic in Children.Insufficient serum caspofungin levels in a paediatric patient on ECMO.Big data analyses for continuous evaluation of pharmacotherapy: A proof of principle with doxapram in preterm infants.Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints.Doxazosin treatment of phaeochromocytoma during pregnancy: placental transfer and disposition in breast milk.A new challenge: suicide attempt using nicotine fillings for electronic cigarettes.Impairment of endogenous melatonin rhythm is related to the degree of chronic kidney disease (CREAM study).Doubt about the feasibility of preemptive genotyping.Different melatonin rhythms and sleep-wake rhythms in patients on peritoneal dialysis, daytime hemodialysis and nocturnal hemodialysis.Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children.Therapeutic Drug Monitoring in Neonates: what makes them unique?Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients.Dried Blood Spots Combined With Ultra-High-Performance Liquid Chromatography-Mass Spectrometry for the Quantification of the Antipsychotics Risperidone, Aripiprazole, Pipamperone, and Their Major Metabolites.Cytochrome P450 2D6 poor metabolism, curvilinearity, and response: an intriguing observation requiring integration of psychopharmacology into pharmacogenetics.In Vitro Adsorption of Analgosedative Drugs in New Extracorporeal Membrane Oxygenation Circuits.Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug.Identification and quantification of the antipsychotics risperidone, aripiprazole, pipamperone and their major metabolites in plasma using ultra-high performance liquid chromatography-mass spectrometry.High-throughput quantification of 8 antihypertensive drugs and active metabolites in human plasma using UPLC-MS/MS.Intoxication of a Young Girl Reveals the Pitfalls of GHB Rapid Screening.The effects of kidney transplantation on sleep, melatonin, circadian rhythm and quality of life in kidney transplant recipients and living donors.
P50
Q27334946-2E149FA4-8983-4D54-8301-F6FDA2A3F0B1Q35059104-527BDBB7-5D93-472F-8988-4166603F24B7Q35747766-67582E48-99CF-42F0-8E99-A2910E674BC0Q36897027-1B06F307-0672-494E-997B-A24C684261CCQ36924082-18F4265C-AB7E-4230-A60D-586DBD685B56Q37156278-1EC67E1F-D125-4FE4-9C0B-F403EDA18D8EQ37186935-16D7DB24-BEE8-4273-8A69-61D065376F30Q37630778-FA8AD7E5-89D1-403A-8754-BB49C59AC99EQ38015152-19625C6E-D990-4BC5-A2A6-3B5C410B99C3Q38128700-B2490B3E-5425-4D08-9B7F-E2C2E1844F4AQ38691788-DAE6831C-ABB8-451A-AC64-8230D991E027Q38691804-E73F3E08-1A2A-422B-9C20-20DFFA92F127Q38809021-69A3AE33-5943-451E-90E5-5803E265AFB8Q38860906-7FD00970-0FB5-48D2-9E57-DED94B748F88Q38972539-9FE429EC-D022-41D0-86AA-EE985540446FQ40068734-5CACD295-7693-470B-A980-F7C0616789F5Q40069998-5237870E-D712-4FD5-88DB-64EB1B67D6A4Q40112992-A63E31BD-5970-43A0-B520-FC55447BE0EEQ40170977-C9EBE35B-AEC1-4699-B5CF-FCD394D6C4E0Q41089049-A4BD9B16-4946-4EB2-B53C-0914D2726137Q41364047-BE2F1C64-E7F1-4513-B6A1-8ECE9D76D6CAQ41860910-2AB973D8-BAF4-4A27-90FD-43B4F656F624Q41996606-6F3DAA02-FB87-4D7F-AF31-5E485CE5B784Q42101630-9115D918-6176-4002-ADE5-AC3B0DDAC6FCQ42382850-EE222980-457B-4467-8F01-2B5ACFB004C7Q43055945-86569E96-598E-4C92-B549-56727649169BQ43273907-134A47D7-E596-4AFC-AE8F-217895314FE7Q45377275-EAE78101-3DFB-4B41-82DE-186324E7EFA2Q45930230-7C5E4CFE-3565-4774-94B3-3E6598630359Q47600302-3900F488-6A1E-4DFE-AAEB-8C6709D82296Q47740593-C262E012-CD23-4A73-9974-0EA06B4E7B80Q47901754-6B4825BD-E548-4FD9-AEA3-EBC0F646D6E6Q47974867-4AFA8DD0-008A-47CF-B91E-B283D7B4E57EQ48404442-B83E6766-29A0-4EED-8AB3-5F6BAFE2750BQ48503960-73B5073C-A30A-4296-809C-A46C42B3EE1FQ48637648-5F6E9036-0A88-43EF-A3BE-2958784856AEQ50343842-541A1BEF-A352-4AF9-8D47-FBA400A56540Q50551928-621BA73A-942C-4E8B-BF84-8632B94EA65CQ50797788-5C73690C-3015-4F1B-8AB5-A1ECFC1D7BA3Q52656122-73ACA812-9104-48A9-8030-BE6CF9802471
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0002-1202-3643
@en
name
Birgit Koch
@ast
Birgit Koch
@en
Birgit Koch
@es
Birgit Koch
@nl
type
label
Birgit Koch
@ast
Birgit Koch
@en
Birgit Koch
@es
Birgit Koch
@nl
prefLabel
Birgit Koch
@ast
Birgit Koch
@en
Birgit Koch
@es
Birgit Koch
@nl
P106
P1153
24780943000
P31
P496
0000-0002-1202-3643